CORT | Ticker Profile - Titan Protect

CORT

Corcept Therapeutics Incorporated

Healthcare · Biotechnology · NCM

$72.62

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$7.2B

Total market value of the company

Trailing P/E

190.43

Expensive — high growth expected

Forward P/E

56.80

Based on estimated future earnings — lower means cheaper

Rev Growth

+4.9%

Year-over-year revenue change

Profit Margin

6.2%

How much profit the company keeps from each dollar of revenue

ROE

7.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$75.00

+3% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

https://www.corcept.com

Country: United States Employees: 730 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.809

Good returns relative to risk taken

Kelly Fraction

0.1172

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.663

Acceptable balance between returns and drawdown risk

Annual Return

47.6%

Historical annualised return based on price data

Max Drawdown

-71.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.36

Very low correlation to market moves

52W High

$91.00

20% below the year high

52W Low

$28.66

153% above the year low

Avg Volume

1,450,554

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.35

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.51

Meaningful debt load — monitor closely

Current Ratio

2.86

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.53

Like current ratio but excludes inventory — stricter test

Gross Margin

98.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-30.1%

Profit from core operations before interest and tax

Free Cash Flow

$116M

Positive — the business generates more cash than it spends

Revenue (TTM)

$769M

Total revenue over the last 12 months

Net Income

$47M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$110.00

Target Median

$75.00

Target Low

$50.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go